However, Ozempic is intended to be used to treat Type 2 diabetes, not weight loss
L.Molina-PorcelL.CorradaM
Phng php n king y khoa d duy tr L tng cho nhng ngi gp phi nhng vn ny Cht bo ni tng Ti mun n king D dng phc hi Thuc tim GIP/GLP-1 l g
Patients reported lower rates of nausea and vomiting, and no new safety concerns were identified
For those considering GLP-1 medications like Wegovy or Ozempic, insurance can make a big difference
Clinical evidence: key trials and outcomes The kidney-protective potential of SGLT2 inhibitors was first identified in cardiovascular outcome trials, including Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus PatientsRemoving Excess Glucose (EMPA-REG OUTCOME) [36], Canagliflozin Cardiovascular Assessment Study (CANVAS) [37], and Dapagliflozin Effect on Cardiovascular EventsThrombolysis in Myocardial Infarction 58 (DECLARETIMI 58) [38]